| Affiliation: | 1. Pediatric Cardiology Department, Ramón y Cajal University Hospital, Madrid, Spain;2. Neonatology Department, Hospital Clínico San Carlos, Madrid, Spain;3. Neonatology Department, La Paz University Hospital, Madrid, Spain;4. Department of Pharmacology, School of Medicine, University Complutense of Madrid, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Ciber Enfermedades Respiratorias (CIBERES), Madrid, Spain;5. Cell & Gene Therapies Laboratory,Niño Jesus University Hospita, Madrid, Spain;6. Pediatric Cardiology Department, La Paz University Hospital, Madrid, Spain |
| Abstract: | BackgroundBronchopulmonary dysplasia (BPD) is the most prevalent sequelae of premature birth, for which therapeutic options are currently limited. Mesenchymal stromal cells (MSCs) are a potential therapy for prevention or reversal of BPD.Series of casesWe report on two infants with severe BPD in whom off-label treatment with repeated intravenous doses of allogeneic bone marrow–derived MSCs were administered. We analyzed the temporal profile of serum and tracheal cytokines and growth factors as well as safety, tolerability and clinical response. The administration of repeated intravenous doses of MSCs in two human babies with severe and advanced BPD was feasible and safe and was associated with a decrease of pro-inflammatory molecules and lung injury biomarkers. Both patients were at very advanced stages of BPD with very severe lung fibrosis and did not survive the disease.ConclusionsMSCs are a promising therapy for BPD, but they should be administered in early stages of the disease. |
